Prolonged Dysfunction of Astrocytes and Activation of Microglia Accelerate Degeneration of Dopaminergic Neurons in the Rat Substantia Nigra and Block Compensation of Early Motor Dysfunction Induced by 6-OHDA

Molecular Neurobiology

Volumn 55, Issue 4, 2018, Pages 3049-3066

  Kuter, Katarzyna ^a   Olech, Łukasz ^a   Głowacka, Urszula ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Astroglia; Behavioral compensation; Early Parkinson s disease; Fluorocitrate; Microglia; Neuron glia interaction

Indexed keywords

DOPAMINE; FLUOROCITRIC ACID; OXIDOPAMINE; CITRIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; MALE; MICROGLIA; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NONHUMAN; RAT; SUBSTANTIA NIGRA; ANIMAL; ANIMAL BEHAVIOR; CELL DEATH; METABOLISM; MOTOR ACTIVITY; NERVE DEGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; TIME FACTOR; WISTAR RAT;

ANIMALS; ASTROCYTES; BEHAVIOR, ANIMAL; CELL DEATH; CITRATES; DOPAMINE; DOPAMINERGIC NEURONS; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; MICROGLIA; MOTOR ACTIVITY; NERVE DEGENERATION; OXIDOPAMINE; PHENOTYPE; RATS, WISTAR; SUBSTANTIA NIGRA; TIME FACTORS;

EID: 85018417231     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-017-0529-z     Document Type: Article

References (87)

1. Hornykiewicz O (1998) Biochemical aspects of Parkinson’s disease. Neurology 51(2 Suppl 2):S2–S9
2. Kuramoto L, Cragg J, Nandhagopal R, Mak E, Sossi V, de la Fuente-Fernández R, Stoessl AJ, Schulzer M (2013) The nature of progression in Parkinson’s disease: an application of non-linear, multivariate, longitudinal random effects modelling. PLoS One 8(10):e76595. doi:10.1371/journal.pone.0076595
3. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13(7):290–296
4. Zigmond MJ (1997) Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism. Neurobiol Dis 4(3–4):247–253. doi:10.1006/nbdi.1997.0157
5. Bezard E, Gross CE (1998) Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog Neurobiol 55(2):93–116
6. Robinson TE, Mocsary Z, Camp DM, Whishaw IQ (1994) Time course of recovery of extracellular dopamine following partial damage to the nigrostriatal dopamine system. J Neurosci 14(5 Pt 1):2687–2696
7. Zoli M, Torri C, Ferrari R, Jansson A, Zini I, Fuxe K, Agnati LF (1998) The emergence of the volume transmission concept. Brain Res Brain Res Rev 26(2–3):136–147
8. Bezard E, Crossman AR, Gross CE, Brotchie JM (2001) Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson’s disease. FASEB J 15(6):1092–1094
9. Bezard E, Gross CE, Brotchie JM (2003) Presymptomatic compensation in Parkinson’s disease is not dopamine-mediated. Trends Neurosci 26(4):215–221. doi:10.1016/S0166-2236(03)00038-9
10. Fuxe K, Dahlström AB, Jonsson G, Marcellino D, Guescini M, Dam M, Manger P, Agnati L (2010) The discovery of central monoamine neurons gave volume transmission to the wired brain. Prog Neurobiol 90(2):82–100. doi:10.1016/j.pneurobio.2009.10.012
11. Barrio JR, Huang SC, Melega WP, Yu DC, Hoffman JM, Schneider JS, Satyamurthy N, Mazziotta JC et al (1990) 6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures. J Neurosci Res 27(4):487–493. doi:10.1002/jnr.490270408
12. Sossi V, de La Fuente-Fernández R, Holden JE, Doudet DJ, McKenzie J, Stoessl AJ, Ruth TJ (2002) Increase in dopamine turnover occurs early in Parkinson’s disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. J Cereb Blood Flow Metab 22(2):232–239. doi:10.1097/00004647-200202000-00011
13. Collier TJ, Kanaan NM, Kordower JH (2011) Ageing as a primary risk factor for Parkinson’s disease: evidence from studies of non-human primates. Nat Rev Neurosci 12(6):359–366. doi:10.1038/nrn3039
14. Peng SL, Dumas JA, Park DC, Liu P, Filbey FM, McAdams CJ, Pinkham AE, Adinoff B et al (2014) Age-related increase of resting metabolic rate in the human brain. NeuroImage 98:176–183. doi:10.1016/j.neuroimage.2014.04.078
15. Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, McKenzie J, McCormick S, Ruth TJ et al (2011) Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson’s disease. Brain 134(Pt 11):3290–3298. doi:10.1093/brain/awr233
16. Hu X, Yuan Y, Wang D, Su Z (2016) Heterogeneous astrocytes: active players in CNS. Brain Res Bull 125:1–18. doi:10.1016/j.brainresbull.2016.03.017
17. Rangasamy SB, Soderstrom K, Bakay RA, Kordower JH (2010) Neurotrophic factor therapy for Parkinson’s disease. Prog Brain Res 184:237–264. doi:10.1016/S0079-6123(10)84013-0
18. Fernandez-Fernandez S, Almeida A, Bolaños JP (2012) Antioxidant and bioenergetic coupling between neurons and astrocytes. Biochem J 443(1):3–11. doi:10.1042/BJ20111943
19. Norden DM, Trojanowski PJ, Villanueva E, Navarro E, Godbout JP (2016) Sequential activation of microglia and astrocyte cytokine expression precedes increased Iba-1 or GFAP immunoreactivity following systemic immune challenge. Glia 64(2):300–316. doi:10.1002/glia.22930
20. Norden DM, Muccigrosso MM, Godbout JP (2015) Microglial priming and enhanced reactivity to secondary insult in aging, and traumatic CNS injury, and neurodegenerative disease. Neuropharmacology 96(Pt A):29–41. doi:10.1016/j.neuropharm.2014.10.028
21. Liu W, Tang Y, Feng J (2011) Cross talk between activation of microglia and astrocytes in pathological conditions in the central nervous system. Life Sci 89(5–6):141–146. doi:10.1016/j.lfs.2011.05.011
22. Gonzalez-Perez O, Quiñones-Hinojosa A (2012) Astrocytes as neural stem cells in the adult brain. J Stem Cells 7(3):181–188
23. De Pittà M, Brunel N (2016) Modulation of synaptic plasticity by glutamatergic gliotransmission: a modeling study. Neural Plast 2016:7607924. doi:10.1155/2016/7607924
24. De Pittà M, Brunel N, Volterra A (2016) Astrocytes: orchestrating synaptic plasticity? Neuroscience 323:43–61. doi:10.1016/j.neuroscience.2015.04.001
25. Canals S, Larrosa B, Pintor J, Mena MA, Herreras O (2008) Metabolic challenge to glia activates an adenosine-mediated safety mechanism that promotes neuronal survival by delaying the onset of spreading depression waves. J Cereb Blood Flow Metab 28(11):1835–1844. doi:10.1038/jcbfm.2008.71
26. Rossi D, Martorana F, Brambilla L (2011) Implications of gliotransmission for the pharmacotherapy of CNS disorders. CNS Drugs 25(8):641–658. doi:10.2165/11593090-000000000-00000
27. Rossi D (2015) Astrocyte physiopathology: at the crossroads of intercellular networking, inflammation and cell death. Prog Neurobiol 130:86–120. doi:10.1016/j.pneurobio.2015.04.003
28. Bolaños JP (2016) Bioenergetics and redox adaptations of astrocytes to neuronal activity. J Neurochem. doi:10.1111/jnc.13486
29. Falkowska A, Gutowska I, Goschorska M, Nowacki P, Chlubek D, Baranowska-Bosiacka I (2015) Energy metabolism of the brain, including the cooperation between astrocytes and neurons, especially in the context of glycogen metabolism. Int J Mol Sci 16(11):25959–25981. doi:10.3390/ijms161125939
30. Liang CL, Wang TT, Luby-Phelps K, German DC (2007) Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson’s disease. Exp Neurol 203(2):370–380. doi:10.1016/j.expneurol.2006.08.015
31. Kim-Han JS, Antenor-Dorsey JA, O’Malley KL (2011) The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons. J Neurosci 31(19):7212–7221. doi:10.1523/JNEUROSCI.0711-11.2011
32. Pacelli C, Giguère N, Bourque MJ, Lévesque M, Slack RS, Trudeau L (2015) Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons. Curr Biol 25(18):2349–2360. doi:10.1016/j.cub.2015.07.050
33. Verkhratsky A, Parpura V (2016) Astrogliopathology in neurological, neurodevelopmental and psychiatric disorders. Neurobiol Dis 85:254–261. doi:10.1016/j.nbd.2015.03.025
34. Pekny M, Pekna M, Messing A, Steinhäuser C, Lee JM, Parpura V, Hol EM et al (2016) Astrocytes: a central element in neurological diseases. Acta Neuropathol 131(3):323–345. doi:10.1007/s00401-015-1513-1
35. Capani F, Quarracino C, Caccuri R, Sica RE (2016) Astrocytes as the main players in primary degenerative disorders of the human central nervous system. Front Aging Neurosci 8:45. doi:10.3389/fnagi.2016.00045
36. Jyothi HJ, Vidyadhara DJ, Mahadevan A, Philip M, Parmar SK, Manohari SG, Shankar SK, Raju TR et al (2015) Aging causes morphological alterations in astrocytes and microglia in human substantia nigra pars compacta. Neurobiol Aging 36(12):3321–3333. doi:10.1016/j.neurobiolaging.2015.08.024
37. Lee HJ, Kim C, Lee SJ (2010) Alpha-synuclein stimulation of astrocytes: potential role for neuroinflammation and neuroprotection. Oxidative Med Cell Longev 3(4):283–287. doi:10.4161/oxim.3.4.12809
38. Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, Masliah E et al (2010) Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 285(12):9262–9272. doi:10.1074/jbc.M109.081125
39. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H (2000) NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson’s disease brains. Acta Neuropathol 99(1):14–20
40. Braak H, Sastre M, Del Tredici K (2007) Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson’s disease. Acta Neuropathol 114(3):231–241. doi:10.1007/s00401-007-0244-3
41. Halliday GM, Stevens CH (2011) Glia: initiators and progressors of pathology in Parkinson’s disease. Mov Disord 26(1):6–17. doi:10.1002/mds.23455
42. Sathe K, Maetzler W, Lang JD, Mounsey RB, Fleckenstein C, Martin HL, Schulte C, Mustafa S et al (2012) S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway. Brain 135(Pt 11):3336–3347. doi:10.1093/brain/aws250
43. Werner CJ, Heyny-von Haussen R, Mall G, Wolf S (2008) Proteome analysis of human substantia nigra in Parkinson’s disease. Proteome Sci 6:8. doi:10.1186/1477-5956-6-8
44. Robinson TE, Castañeda E, Whishaw IQ (1990) Compensatory changes in striatal dopamine neurons following recovery from injury induced by 6-OHDA or methamphetamine: a review of evidence from microdialysis studies. Can J Psychol 44(2):253–275
45. Paulsen RE, Contestabile A, Villani L, Fonnum F (1987) An in vivo model for studying function of brain tissue temporarily devoid of glial cell metabolism the use of fluorocitrate. J Neurochem 48(5):1377–1385
46. Zielke HR, Zielke CL, Baab PJ, Tildon JT (2007) Effect of fluorocitrate on cerebral oxidation of lactate and glucose in freely moving rats. J Neurochem 101(1):9–16. doi:10.1111/j.1471-4159.2006.04335.x
47. Zielke HR, Zielke CL, Baab PJ (2009) Direct measurement of oxidative metabolism in the living brain by microdialysis: a review. J Neurochem 109(Suppl 1):24–29. doi:10.1111/j.1471-4159.2009.05941.x
48. McCall MA, Gregg RG, Behringer RR, Brenner M, Delaney CL, Galbreath EJ, Zhang CL, Pearce RA et al (1996) Targeted deletion in astrocyte intermediate filament (Gfap) alters neuronal physiology. Proc Natl Acad Sci U S A 93(13):6361–6366
49. Cui W, Allen ND, Skynner M, Gusterson B, Clark AJ (2001) Inducible ablation of astrocytes shows that these cells are required for neuronal survival in the adult brain. Glia 34(4):272–282
50. Nishiyama H, Knopfel T, Endo S, Itohara S (2002) Glial protein S100B modulates long-term neuronal synaptic plasticity. Proc Natl Acad Sci U S A 99(6):4037–4042. doi:10.1073/pnas.052020999
51. Nishiyama H, Takemura M, Takeda T, Itohara S (2002) Normal development of serotonergic neurons in mice lacking S100B. Neurosci Lett 321(1–2):49–52
52. Lee HS, Ghetti A, Pinto-Duarte A, Wang X, Dziewczapolski G, Galimi F, Huitron-Resendiz S, Piña-Crespo JC et al (2014) Astrocytes contribute to gamma oscillations and recognition memory. Proc Natl Acad Sci U S A 111(32):E3343–E3352. doi:10.1073/pnas.1410893111
53. Kuter K, Kratochwil M, Berghauzen-Maciejewska K, Głowacka U, Sugawa MD, Ossowska K, Dencher NA (2016) Adaptation within mitochondrial oxidative phosphorylation supercomplexes and membrane viscosity during degeneration of dopaminergic neurons in an animal model of early Parkinson’s disease. Biochim Biophys Acta 1862(4):741–753. doi:10.1016/j.bbadis.2016.01.022
54. Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates. Academic Press, San Diego
55. Kolasiewicz W, Kuter K, Berghauzen K, Nowak P, Schulze G, Ossowska K (2012) 6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson’s disease increase the harmaline-induced tremor in rats. Brain Res 1477:59–73. doi:10.1016/j.brainres.2012.08.015
56. Berghauzen-Maciejewska K, Kuter K, Kolasiewicz W, Głowacka U, Dziubina A, Ossowska K, Wardas J (2014) Pramipexole but not imipramine or fluoxetine reverses the “depressive-like” behaviour in a rat model of preclinical stages of Parkinson’s disease. Behav Brain Res 271:343–353. doi:10.1016/j.bbr.2014.06.029
57. Kuter K, Kolasiewicz W, Gołembiowska K, Dziubina A, Schulze G, Berghauzen K, Wardas J, Ossowska K (2011) Partial lesion of the dopaminergic innervation of the ventral striatum induces “depressive-like” behavior of rats. Pharmacol Rep 63(6):1383–1392
58. Kuter K, Smiałowska M, Wierońska J, Zieba B, Wardas J, Pietraszek M, Nowak P, Biedka I et al (2007) Toxic influence of subchronic paraquat administration on dopaminergic neurons in rats. Brain Res 1155:196–207. doi:10.1016/j.brainres.2007.04.018
59. Haan C, Behrmann I (2007) A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background. J Immunol Methods 318(1–2):11–19. doi:10.1016/j.jim.2006.07.027
60. Welinder C, Ekblad L (2011) Coomassie staining as loading control in Western blot analysis. J Proteome Res 10(3):1416–1419. doi:10.1021/pr1011476
61. Emsley JG, Macklis JD (2006) Astroglial heterogeneity closely reflects the neuronal-defined anatomy of the adult murine CNS. Neuron Glia Biol 2(3):175–186. doi:10.1017/S1740925X06000202
62. Oberheim NA, Goldman SA, Nedergaard M (2012) Heterogeneity of astrocytic form and function. Methods Mol Biol 814:23–45. doi:10.1007/978-1-61779-452-0_3
63. Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, Xing Y, Lubischer JL et al (2008) A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 28(1):264–278. doi:10.1523/JNEUROSCI.4178-07.2008
64. Strömberg I, Björklund H, Dahl D, Jonsson G, Sundström E, Olson L (1986) Astrocyte responses to dopaminergic denervations by 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as evidenced by glial fibrillary acidic protein immunohistochemistry. Brain Res Bull 17(2):225–236
65. Henning J, Strauss U, Wree A, Gimsa J, Rolfs A, Benecke R, Gimsa U (2008) Differential astroglial activation in 6-hydroxydopamine models of Parkinson’s disease. Neurosci Res 62(4):246–253. doi:10.1016/j.neures.2008.09.001
66. Hol EM, Pekny M (2015) Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol 32:121–130. doi:10.1016/j.ceb.2015.02.004
67. Takuma K, Baba A, Matsuda T (2004) Astrocyte apoptosis: implications for neuroprotection. Prog Neurobiol 72(2):111–127. doi:10.1016/j.pneurobio.2004.02.001
68. Bribián A, Figueres-Oñate M, Martín-López E, López-Mascaraque L (2016) Decoding astrocyte heterogeneity: new tools for clonal analysis. Neuroscience 323:10–19. doi:10.1016/j.neuroscience.2015.04.036
69. Pellerin L, Magistretti PJ (1994) Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci U S A 91(22):10625–10629
70. Hassel B, Paulsen RE, Johnsen A, Fonnum F (1992) Selective inhibition of glial cell metabolism in vivo by fluorocitrate. Brain Res 576(1):120–124
71. Hassel B, Sonnewald U, Unsgård G, Fonnum F (1994) NMR spectroscopy of cultured astrocytes: effects of glutamine and the gliotoxin fluorocitrate. J Neurochem 62(6):2187–2194
72. Fonnum F, Johnsen A, Hassel B (1997) Use of fluorocitrate and fluoroacetate in the study of brain metabolism. Glia 21(1):106–113
73. Hirose S, Umetani Y, Amitani M, Hosoi R, Momosaki S, Hatazawa J, Gee A, Inoue O (2007) Role of NMDA receptors in the increase of glucose metabolism in the rat brain induced by fluorocitrate. Neurosci Lett 415(3):259–263. doi:10.1016/j.neulet.2007.01.031
74. Hassel B, Westergaard N, Schousboe A, Fonnum F (1995) Metabolic differences between primary cultures of astrocytes and neurons from cerebellum and cerebral cortex. Effects of fluorocitrate. Neurochem Res 20(4):413–420
75. Willoughby JO, Mackenzie L, Broberg M, Thoren AE, Medvedev A, Sims NR, Nilsson M (2003) Fluorocitrate-mediated astroglial dysfunction causes seizures. J Neurosci Res 74(1):160–166. doi:10.1002/jnr.10743
76. Rossi D, Volterra A (2009) Astrocytic dysfunction: insights on the role in neurodegeneration. Brain Res Bull 80(4–5):224–232. doi:10.1016/j.brainresbull.2009.07.012
77. Delaney CL, Brenner M, Messing A (1996) Conditional ablation of cerebellar astrocytes in postnatal transgenic mice. J Neurosci 16(21):6908–6918
78. Rodríguez Díaz M, Alonso TJ, Perdomo Diaz J, Gonzalez Hernández T, Castro Fuentes R, Sabate M, Garcia Dopico J (2005) Glial regulation of nonsynaptic extracellular glutamate in the substantia nigra. Glia 49(1):134–142. doi:10.1002/glia.20100
79. McNaught KS, Jenner P (1999) Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. J Neurochem 73(6):2469–2476
80. Chen SH, Oyarzabal EA, Sung YF, Chu CH, Wang Q, Chen SL, Lu RB, Hong JS (2015) Microglial regulation of immunological and neuroprotective functions of astroglia. Glia 63(1):118–131. doi:10.1002/glia.22738
81. Reenilä I, Tuomainen P, Soinila S, Männistö PT (1997) Increase of catechol-O-methyltransferase activity in rat brain microglia after intrastriatal infusion of fluorocitrate, a glial toxin. Neurosci Lett 230(3):155–158
82. Zhang D, Hu X, Qian L, O’Callaghan JP, Hong JS (2010) Astrogliosis in CNS pathologies: is there a role for microglia? Mol Neurobiol 41(2–3):232–241. doi:10.1007/s12035-010-8098-4
83. Meiser J, Weindl D, Hiller K (2013) Complexity of dopamine metabolism. Cell Commun Signal 11(1):34. doi:10.1186/1478-811X-11-34
84. Perez XA, Parameswaran N, Huang LZ, O’Leary KT, Quik M (2008) Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates. J Neurochem 105(5):1861–1872. doi:10.1111/j.1471-4159.2008.05268.x
85. Zigmond MJ, Hastings TG, Perez RG (2002) Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity? Parkinsonism Relat Disord 8(6):389–393
86. Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE (2001) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned Macaque model of Parkinson’s disease. J Neurosci 21(17):6853–6861
87. Dijkstra AA, Ingrassia A, de Menezes RX, van Kesteren RE, Rozemuller AJ, Heutink P, van de Berg WD (2015) Evidence for immune response, axonal dysfunction and reduced endocytosis in the substantia nigra in early stage Parkinson’s disease. PLoS One 10(6):e0128651. doi:10.1371/journal.pone.0128651